Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;103(10):1392-5.
doi: 10.1111/j.1464-410X.2008.08328.x. Epub 2009 Jan 20.

Differences in Side-Effect Duration and Related Bother Levels Between Phosphodiesterase Type 5 Inhibitors

Affiliations
Free article

Differences in Side-Effect Duration and Related Bother Levels Between Phosphodiesterase Type 5 Inhibitors

Joby Taylor et al. BJU Int. .
Free article

Abstract

Objective: To assess whether the longer half-life of tadalafil is associated with longer lasting or more severe side-effects than the other phosphodiesterase type 5 inhibitors (PDE-5Is), as clinical trials have shown that the efficacy and safety of the three available are similar, but tadalafil has a half-life four times longer than the other two drugs.

Patients and methods: Treatment-naive men beginning PDE5-I therapy were recruited from a specialist clinic. Data on the type and duration of drug-associated side-effects were collected prospectively. Levels of bother were assessed with a visual analogue scale (VAS). Differences in type, duration and bother of side-effect were compared between drugs.

Results: In all, 409 men provided data; there were no differences between drugs in the proportion of men responding, or the overall prevalence of side-effects. The mean duration of side-effects with tadalafil was 14.9 h, compared to 3.9 and 7.7 h for sildenafil and vardenafil. Of men taking tadalafil, 30% had side-effects lasting >12 h. There were no differences in mean VAS scores between the drugs. Individual side-effects caused similar levels of bother, except for facial flushing, which was less bothersome.

Conclusions: Men taking tadalafil are at risk of prolonged side-effects, although levels of bother associated with these side-effects are not significantly greater than those seen with short-acting PDE5-Is.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

MeSH terms

Feedback